Lyell Immunopharma, Inc. (LYEL)
Nasdaq: LYEL · Pharmaceutical Preparations · South San Francisco, CA · filing with the SEC since 2020
Who runs Lyell Immunopharma, Inc.
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedChief executive, as filed
Seely Lynn
President and CEO. First filing Jun 2021, latest Nov 12, 2026, 10 filings in all.
Officers reporting now
10
of 17 people with a filing in the last fifteen months
Directors reporting now
7
23 people on the record since 2021
Officerssales are open-market, Nov 12, 2025 to Nov 12, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Seely Lynn | President and CEO | Jun 2021 | Nov 12, 2026 | 6 · $400,000 |
| Hill Stephen J. | Chief Operating Officer | Jun 2021 | Nov 12, 2026 | 6 · $100,000 |
| Lee Gary K. | Chief Scientific Officer | Feb 2022 | Nov 12, 2026 | 6 · $100,000 |
| Bulis Veronica Sanchez | VP, Corporate Controller | Nov 2025 | Nov 12, 2026 | 6 · $100,000 |
| Aguirre Jarrad Mattieu | Chief Medical Officer | Sep 2026 | Oct 13, 2026 | 1 · $0.00 |
| Shook David | Chief Medical Officer | Jun 2025 | Sep 10, 2026 | 2 · $0.00 |
| Klausner Richard | Executive Chairman | Jun 2021 | Jun 12, 2026 | none |
| Shah Smital | Chief Fin. and Bus. Officer | Mar 2026 | Mar 16, 2026 | none |
| Meltz Mark A | General Counsel | Jun 2025 | Feb 11, 2026 | none |
| Newton Charles W. | Chief Financial Officer | Jun 2021 | Aug 22, 2025 | none |
Directorssales are open-market, Nov 12, 2025 to Nov 12, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Nelsen Robert | director | Jun 2021 | Nov 5, 2026 | none |
| Bachleda Mark | director | Jun 2025 | Jun 12, 2026 | none |
| Brawley Otis W | director | Jun 2021 | Jun 12, 2026 | none |
| Friedman Cathy | director | Jun 2021 | Jun 12, 2026 | none |
| Nabel Elizabeth G | director | Jun 2021 | Jun 12, 2026 | none |
| Ramachandra Sumant | director | Nov 2024 | Jun 12, 2026 | none |
| Rieflin William Jl | director | Jun 2021 | Jun 12, 2026 | none |
Owners of more than 10% of a classsales are open-market, Nov 12, 2025 to Nov 12, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Arch Venture Fund Ix Overage, L.P. | 10% owner | Jun 2021 | Nov 5, 2026 | none |
| Arch Venture Fund Ix, L.P. | 10% owner | Jun 2021 | Nov 5, 2026 | none |
| Arch Venture Fund Xiii, L.P. | 10% owner | Jul 2025 | Nov 5, 2026 | none |
| Arch Venture Partners Ix Overage, L.P. | 10% owner | Jun 2021 | Nov 5, 2026 | none |
| Arch Venture Partners Ix, L.P. | 10% owner | Jun 2021 | Nov 5, 2026 | none |
| Arch Venture Partners Ix, LLC | 10% owner | Jun 2021 | Nov 5, 2026 | none |
| Arch Venture Partners Xiii, L.P. | 10% owner | Jul 2025 | Nov 5, 2026 | none |
| Arch Venture Partners Xiii, LLC | 10% owner | Jul 2025 | Nov 5, 2026 | none |
| Berns Paul L | 10% owner | Jul 2025 | Nov 5, 2026 | none |
| Burow Kristina | 10% owner | Jul 2025 | Nov 5, 2026 | none |
| Bybee Clinton | 10% owner | Jun 2021 | Nov 5, 2026 | none |
| Crandell Keith | 10% owner | Jun 2021 | Nov 5, 2026 | none |
| Gillis Steven | 10% owner | Jul 2025 | Nov 5, 2026 | none |
| Innovative Cellular Therapeutics Holdings Ltd | 10% owner | Jun 2026 | Jul 27, 2026 | 2 · $0.00 |
Earlier names on the record7, newest filing first
Lang Matthew · officer · last filing Feb 2025Bishop Hans Edgar · director · last filing Jun 2024Albertson Tina M. · officer · last filing Feb 2023Thompson Rahsaan · officer · last filing Feb 2023Homans Elizabeth · officer · last filing Mar 2022Turner Heather D · officer · last filing Mar 2022Glaxosmithkline PLC · 10% owner · last filing Jun 2021
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.